Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages

  Jensterle, Mojca ^a   Kocjan, Tomaz ^a   Janez, Andrej ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMINOPYRIDINES; BENZAMIDES; BODY WEIGHT; CYCLOPROPANES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INSULIN; MENSTRUAL CYCLE; METFORMIN; MOLECULAR TARGETED THERAPY; OBESITY; PHOSPHODIESTERASE 4 INHIBITORS; POLYCYSTIC OVARY SYNDROME; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84905821655     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1430     Document Type: Article

References (15)

1. Vezzosi D, Bertherat J. Phosphodiesterases in endocrine physiology and disease. Eur J Endocrinol. 2011;165(2):177-188.
2. Chen C, Wickenheisser J, Ewens KG, et al. PDE8A genetic variation, polycystic ovary syndrome and androgen levels in women.MolHum Reprod. 2009;15(8):459-469.
3. Tsai LC, Beavo JA. The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis. Curr Opin Pharmacol. 2011;11(6):670-675.
4. Bingham J, Sudarsanam S, Srinivasan S. Profiling human phosphodiesterase genes and splice isoforms. Biochem Biophys Res Commun. 2006;350(1):25-32.
5. Sasseville M, Albuz FK, Cote N, Guillemette C, Gilchrist RB, Richard FJ. Characterization of novel phosphodiesterases in the bovine ovarian follicle. Biol Reprod. 2009;81(2):415-425.
6. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685-694.
7. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374(9691):695-703.
8. Wouters EF, Bredenbröker D, Teichmann P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(9):E1720-E725.
9. Vollert S, Kaessner N, Heuser A, et al. The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice. Diabetologia. 2012;55(10):2779-2788.
10. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93(7): 2670-2678.
11. Kahal H, Abouda G, Rigby AS, Coady AM, Kilpatrick ES, Atkin SL. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). 2013 Nov
12. [Epub ahead of print].
13. Jensterle M, Kocjan T, Pfeifer M, Kravos NA, Janez AL. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur J Endocrinol. 2013 Dec 20. [Epub ahead of print]
14. American Diabetes Association. Standards of medical care in diabetes, 2013. Diabetes Care. 2013;36(suppl 1):S67-S74.
15. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (London, England: 1979). 2012;122(6):253-570.